Label Changes for:

Cayston (aztreonam for inhalation solution)

September 2012

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2012

 

6 ADVERSE REACTIONS

6.2 Postmarketing Experience

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS:  

  • Dyspnea

MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS:

  • Arthralgia, Joint swelling
     

 

Hide
(web5)